| Literature DB >> 27994690 |
Nishikant Avinash Damle1, Madhavi Tripathi1, Partha Sarathi Chakraborty1, Manas Kumar Sahoo1, Chandrasekhar Bal1, Shipra Aggarwal2, Geetanjali Arora1, Praveen Kumar1, Rajeev Kumar1, Ravikant Gupta1.
Abstract
68Ga-Prostate specific membrane antigen- N,N'-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid- positron emission tomography/computed tomography or 68 Ga- HBED-CC-PSMA PET/CT, popularly known as PSMA PET/CT, is able to detect a small volume of recurrent prostate carcinoma (PC) when there is a prostate specific antigen (PSA) rise on follow-up after prostatectomy or other definitive treatment for PC. The use of PSMA PET/CT in the initial staging in PC is uncertain at this time. Clinical studies are underway to define its exact role in the management of the disease. At the same time it is important to be aware of unexpected sites of uptake of this ligand. We present here the case of a 62-year-old male patient who underwent prostatectomy for adenocarcinoma prostate. He also had a long-standing left solitary thyroid nodule (STN). Four months after surgery, he had a rising trend in serum PSA levels on three occasions, but the absolute value was less than 4 at all times. He underwent a 68Ga-PSMA-HBED-CC PET/CT, but it did not reveal any recurrent/metastatic site of disease. However, there was increased tracer uptake in the left STN. Fine needle aspiration cytology revealed features of atypia of undetermined significance, Bethesda category III. The patient underwent a left hemithyroidectomy and the histopathology showed features of a follicular adenoma.Entities:
Keywords: 68Gallium; PET/CT; PSMA; Prostate carcinoma
Year: 2016 PMID: 27994690 PMCID: PMC5135692 DOI: 10.1007/s13139-016-0408-y
Source DB: PubMed Journal: Nucl Med Mol Imaging ISSN: 1869-3474